Dostarlimab demonstrated durable antitumor activity and safety in patients with dMMR/MSI-H EC. Biomarkers associated with EC may identify patients likely to respond to dostarlimab. See related commentary by Jangra and Dhani, p. 4521.
No takes yet. Share an insight, caveat, or question.
Oaknin et al. (2023) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: